This site is intended for healthcare professionals only
LoginRegister
Sun Pharma, Philogen complete patient enrollment in Phase III trial for Soft Tissue SarcomaConduct Phase III CT: CDSCO Panel Tells Sun Pharma on Liraglutide solution for injection PFP
Justify rationality for FDC Sitagliptin, Lobeglitazon: CDSCO Panel Tells Synokem PharmaJustify rationality for FDC Sitagliptin, Lobeglitazon: CDSCO Panel Tells Synokem Pharma
Lupin Partners with TB Alliance to Advance Telacebec for TB, Leprosy and Buruli UlcerMerck Life Science arm, Department of Atomic Energy collaborate for heavy water supply
Thermo Fisher expands India footprint with Customer Experience, Bioprocess Design Centers at Genome ValleyThermo Fisher Scientific bags USFDA clearance for Preeclampsia risk assessment assays
Glenmark Pharma posts 12.3 percent decline in Q4 profit as domestic sales weakenGlenmark Pharma posts 12.3 percent decline in Q4 profit as domestic sales weaken
Abbotts Phensedyl Supply Chain Under Scanner After Ghaziabad Seizure, Codeine Diversion Probe WidensAbbott gets USFDA nod for spinal cord stimulation devices for chronic back pain in people who have...
Glenmarks Telma Surpasses Rs 1,000 Crore Revenue, Recognized in Harvard Case StudyGlenmark gets CDSCO panel nod for Phase III CT of antidiabetic FDC drug
Patent infringement: Factor Bioscience sues AstraZeneca, Cellectis over gene-editing technologyCureVac files expanded patent lawsuit against Pfizer/BioNTech over mRNA technology
Bharat Biotech partner Ocugen to set up RnD centre in HyderabadBharat Biotech partner Ocugen to set up RnD centre in Hyderabad
Aurobindo Pharma Q3 Net Profit Rises 8% to Rs 910 CrAurobindo Pharma Anakapalli facility gets 4 USFDA observations
AbbVie gets USFDA nod for EPKINLY to treat adult patients with relapsed or refractory Diffuse Large B-Cell LymphomaAbbVie gets USFDA nod for EPKINLY to treat adult patients with relapsed or refractory Diffuse Large...
USFDA nod to Zydus Eluxadoline tablets for irritable bowel syndrome with diarrhoeaZydus Lifesciences reports 25 percent decline in consolidated net profit at Rs 297 crore in Q4
X